Business Description QLT Inc.. The Group's principal activities are to discover, develop, manufacture and commercialise therapeutics for human health care including eye diseases, cancer and dermatological conditions. The products include visudyne, eligard, punctal plug and lemuteporfin. The eligard line of products are used for treatment of prostate cancer. Visudyne has been approved in over 75 countries and eligard is approved in over 60 countries. The Group's products are sold in the United States, Europe, Canada and other countries. On 18-Oct-2007 the Group acquired ForSight Newco II Inc, now known as QLT Plug Delivery Inc.
Competitor Analysis
This analysis compares QLT Inc. with three other companies in closely related industry sectors.
The full Comparative Business Report is available to Subscribers or may be purchased individually. The full report generally includes the following sections:
- Sales Analysis: Recent Sales, Sales Growth, Sales per Employee
- Recent Stock Performance
- Company Valuation Ratios: Price/Earnings, Price/Book Value
- Price/Sales and 52 Week Price change
- Dividend Analysis
- Profitability Analysis: Gross Profit Margin, EBITDA Margin
- Earnings Before Extraordinary Items
- Inventory Analysis
- Research and Development Expenses
- Financial Position: Long Term Debt/Equity, Days Accounts Receivable, Days Inventory
- R&D Expenses/Sales
Not the Report you are looking for?Click here for more browsing options.
* If a currency is not selected, the report will be delivered in the local currency of the company ** Full access limits users to 500 reports per month
Web site and selected data copyright 2008 The Winthrop Corporation. All rights reserved. Selected data copyright 2008, "Worldscope/Disclosure, L.L.C., a Primark affiliate." All rights reserved.
